Valirx (VAL) RNS Announcements

Add to Alert list
Date Time Source Announcement
24 Sep 2019 07:00 AM
RNS
Company Update
10 Sep 2019 05:15 PM
RNS
Holding(s) in Company
10 Sep 2019 07:00 AM
RNS
VAL201 Update
06 Aug 2019 07:00 AM
RNS
Company Update & Change of Adviser
01 Aug 2019 07:00 AM
RNS
New European patent allowance for VAL301
23 Jul 2019 04:02 PM
RNS
Holding(s) in Company
23 Jul 2019 07:00 AM
RNS
Appointment of Joint Broker
10 Jul 2019 07:00 AM
RNS
Marketing and Communications Update
09 Jul 2019 11:14 AM
RNS
Change of Registered Address
04 Jul 2019 07:00 AM
RNS
Update re VAL301
28 Jun 2019 01:33 PM
RNS
Holding(s) in Company
28 Jun 2019 12:31 PM
RNS
Issue of Equity
28 Jun 2019 12:03 PM
RNS
Result of AGM
26 Jun 2019 12:00 PM
RNS
Holding(s) in Company
26 Jun 2019 07:00 AM
RNS
US Notice of Allowance-VAL201 & Metastatic Cancer
25 Jun 2019 02:50 PM
RNS
Further re: Termination of Subscription Agreement
24 Jun 2019 12:45 PM
RNS
Holding(s) in Company
21 Jun 2019 12:00 PM
RNS
Holding(s) in Company
20 Jun 2019 07:00 AM
RNS
Update on VAL201 Clinical Trial
19 Jun 2019 12:00 PM
RNS
Holding(s) in Company
13 Jun 2019 07:00 AM
RNS
Placing, Subscription Agreement & Issue of Warrant
10 Jun 2019 07:00 AM
RNS
Subscription Agreement Update
05 Jun 2019 07:00 AM
RNS
Notice of AGM & Update of Subscription Agreement
31 May 2019 11:07 AM
RNS
Subscription Agreement Update
31 May 2019 10:42 AM
RNS
Holding(s) in Company
30 May 2019 10:30 AM
RNS
Holding(s) in Company
29 May 2019 11:44 AM
RNS
Holding(s) in Company
29 May 2019 07:00 AM
RNS
Final Results
28 May 2019 07:00 AM
RNS
Subscription Agreement Update
23 May 2019 12:02 PM
RNS
Holding(s) in Company
22 May 2019 07:00 AM
RNS
Subscription Agreement Update
13 May 2019 02:00 PM
RNS
Price Monitoring Extension
02 May 2019 07:00 AM
RNS
Acquisition of Intellectual Property& JV Agreement
29 Apr 2019 02:06 PM
RNS
Second Price Monitoring Extn
29 Apr 2019 02:01 PM
RNS
Price Monitoring Extension
29 Apr 2019 11:07 AM
RNS
Second Price Monitoring Extn
29 Apr 2019 11:01 AM
RNS
Price Monitoring Extension
29 Apr 2019 10:55 AM
RNS
Holding(s) in Company
26 Apr 2019 07:00 AM
RNS
Subscription, Convertible Funds and Warrant Issue
15 Apr 2019 07:15 AM
EQS
Valirx (VAL): VAL401 is going forward
26 Mar 2019 07:00 AM
RNS
ValiSeek Update
21 Mar 2019 07:00 AM
RNS
Update on VAL201 & VAL301 Development Progress
21 Feb 2019 11:22 AM
RNS
Placing, Issue of Equity and Warrant
31 Jan 2019 07:00 AM
RNS
New patent grant allowances for VAL301
11 Jan 2019 07:00 AM
RNS
Publication of VAL401 peer-reviewed article
09 Jan 2019 10:41 AM
RNS
ValiRx endorses the Government's new NHS strategy
03 Jan 2019 07:00 AM
RNS
Holding(s) in Company
18 Dec 2018 04:41 PM
RNS
Second Price Monitoring Extn
18 Dec 2018 04:36 PM
RNS
Price Monitoring Extension
18 Dec 2018 11:25 AM
RNS
Issue of Equity / PDMR Shareholdings

ValiRx PLC: A Biotech Innovator on the London Stock Exchange (LSE)

ValiRx PLC, known by its ticker symbol VAL, is a trailblazer in the biotechnology sector. Its performance on the London Stock Exchange (LSE) has been remarkable, with the ValiRx share price reflecting the company's consistent growth and success.

As a member of the LSE, ValiRx PLC aligns with the London Stock Exchange Group's (LSEG) mission of supporting innovative and growing businesses. The LSEG recognises ValiRx PLC as a significant player, contributing to the robust and diverse ecosystem of the LSE.

The ValiRx share price on the LSE not only underscores its financial stability but also its strategic vision in the biotechnology industry. ValiRx PLC's journey on the LSE is a testament to its robust business model and its ability to create value for its stakeholders.

In conclusion, ValiRx PLC's association with the LSE and LSEG symbolises its commitment to growth, innovation, and value creation. As ValiRx PLC continues to thrive on the LSE, it sets the bar high for the biotechnology industry, contributing to the dynamic and diverse ecosystem of the LSEG. With its focus on cancer therapeutics, ValiRx is a key player in the healthcare sector, making strides in medical research and development.

UK 100

Latest directors dealings